CD8A and non-small cell lung carcinoma: In an analysis of stage III/IV patients with NSCLC, comparing 18 responders and 18 non-responders, we found in our cohort of patients that CD8 T cells from responders showed significantly higher PD-1 expression at baseline compared to nonresponders (p = 0.04, Fig. 2A).